About IZY Capital
What makes us different
Izy Capital is a technology focussed advisory and venture capital practice whose sole mission is to work with, incubate and grow the next generation of world leading innovators. We can and do get involved in the journey from idea stage through the entire lifecycle to exit. Our portfolio currently includes companies at the pre-Seed through to post Series A and we take pride in our multi-stage funding capacity, either directly or with our partners. While we remain sector agnostic, we are increasingly biased towards innovations in healthcare technology, EdTech, Blockchain, DeepTech and Machine Learning.
More about how much you will love working with us
We love great founders and expect innovators to have the ability to think creatively, to reimagine industries, be prepared to experiment, think big and be open minded. We listen, guide and will always be on hand. We are not a bucket shop. We are your partner.
Meet The Team
David is the Principal of IZY Capital. A Fellow of the Institute of Chartered Accountants, David has spent the last 20 years as a technology analyst, investment banker and more latterly investor and entrepreneur.
Thomas is a serial entrepreneur with multiple exits across the retail vertical. Thomas leads origination in the US and Canada and is also responsible for scaling strategies for the Izy portfolio.
Joanne Hackett PhD
Joanne leads Izy Capital Healthcare Practice. A scientist, Joanne brings a wealth of experience in the fields of genomics, therapeutics and neural interfaces. She is a visiting fellow at the University of Cambridge, UCL and Imperial and is also the Chair of the Board at BIOS, a global leader in neural interface technology.
George is an Investment Analyst for IZY Capital. He has comprehensive experience of financial analysis, economic research and modelling, twinned with a strong understanding of the dynamics of start-up companies.
Recruited for his knowledge and experience in system design and implementation, Toby supports the team to make informed evidence-based recommendations for the technical aspects of potential investment opportunities.
Technology Executive specialized in software engineering and IT professional services with solid experience in corporate strategy, business development and people management.
Andrew has over a decade of experience as a software developer in the engineering industry. With a passion for blockchain technology, he is an active member of the Ethereum smart contract development community.
Tom Buckland is a digital marketing consultant specializing in SEO. Building dozens of successful SEO campaigns for clients all over the world with the focus on improving organic rankings in relation to ROI.
Front End Developer
Alex has extensive knowledge and drive in the field of web development, as well as a strong experience base working for many large companies.
Abdulkareem is a driven Finance Analyst with an excellent eye for details and a passion for Accountancy
With years of experience in the digital marketing space Abigail is a strong believer in data-driven approaches, crafting tailored strategies that meet clients KPIs.
Josh works with the IZY team to offer design support and skills for developing key investment-focused assets for new start ups and investees, helping to bring clarity and confidence to new ideas and enterprises.
Sub Sector: Hardware
Izy advised Drone Evolution on a recent equity seed round from a syndicate of strategic angel investors. The management team has a proven track record in the industry, having formally run the Drone division for a major facilities management team. Capital is being used to develop a range of commercial applications for the commercial aviation and security markets.Read More
Sub Sector: Software/Clinical Support
TaperMD is a clinical decision support platform pioneered by some of the leading experts in medication management and polypharmacology. Izy is working with the team to develop the platform and assess the market opportunity. The product is currently in trials on three continents and will move to commercialisation in 2019.Read More